Atopic dermatitis: Emerging therapies

Eric Simpson; Jeremy Udkoff; Jenna Borok; Wynnis Tom; Lisa Beck; Lawrence F. Eichenfield

doi:10.12788/j.sder.2017.0137

Atopic dermatitis: Emerging therapies

Eric Simpson, Jeremy Udkoff, Jenna Borok, Wynnis Tom, Lisa Beck, Lawrence F. Eichenfield

Dermatology

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Crisaborole and dupilumab represent the first 2 Food and Drug Administration (FDA)-approved therapies for atopic dermatitis (AD) in more than 15 years, and there are many promising drugs currently in development. This new wave of therapeutics capitalizes on the large body of work clarifying the pathogenesis of AD over the last several decades. In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis.

Original language	English (US)
Pages (from-to)	124-130
Number of pages	7
Journal	Seminars in cutaneous medicine and surgery
Volume	36
Issue number	3
DOIs	https://doi.org/10.12788/j.sder.2017.0137
State	Published - Sep 1 2017

ASJC Scopus subject areas

Surgery
Dermatology

Access to Document

10.12788/j.sder.2017.0137

Cite this

@article{50e0dc30ae304cfebf22d601b5216baf,

title = "Atopic dermatitis: Emerging therapies",

abstract = "Crisaborole and dupilumab represent the first 2 Food and Drug Administration (FDA)-approved therapies for atopic dermatitis (AD) in more than 15 years, and there are many promising drugs currently in development. This new wave of therapeutics capitalizes on the large body of work clarifying the pathogenesis of AD over the last several decades. In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis.",

author = "Eric Simpson and Jeremy Udkoff and Jenna Borok and Wynnis Tom and Lisa Beck and Eichenfield, {Lawrence F.}",

note = "Publisher Copyright: {\textcopyright} 2017 Frontline Medical Communications.",

year = "2017",

month = sep,

day = "1",

doi = "10.12788/j.sder.2017.0137",

language = "English (US)",

volume = "36",

pages = "124--130",

journal = "Seminars in cutaneous medicine and surgery",

issn = "1085-5629",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Atopic dermatitis

T2 - Emerging therapies

AU - Simpson, Eric

AU - Udkoff, Jeremy

AU - Borok, Jenna

AU - Tom, Wynnis

AU - Beck, Lisa

AU - Eichenfield, Lawrence F.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Crisaborole and dupilumab represent the first 2 Food and Drug Administration (FDA)-approved therapies for atopic dermatitis (AD) in more than 15 years, and there are many promising drugs currently in development. This new wave of therapeutics capitalizes on the large body of work clarifying the pathogenesis of AD over the last several decades. In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis.

AB - Crisaborole and dupilumab represent the first 2 Food and Drug Administration (FDA)-approved therapies for atopic dermatitis (AD) in more than 15 years, and there are many promising drugs currently in development. This new wave of therapeutics capitalizes on the large body of work clarifying the pathogenesis of AD over the last several decades. In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=85032834397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032834397&partnerID=8YFLogxK

U2 - 10.12788/j.sder.2017.0137

DO - 10.12788/j.sder.2017.0137

M3 - Article

AN - SCOPUS:85032834397

SN - 1085-5629

VL - 36

SP - 124

EP - 130

JO - Seminars in cutaneous medicine and surgery

JF - Seminars in cutaneous medicine and surgery

IS - 3

ER -

Atopic dermatitis: Emerging therapies

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this